Rationale and Design of the FAIR-HF 2 trial: Ferric Carboxymaltose Assessment of Morbidity and Mortality in Patients with Iron Deficiency and Chronic Heart Failure.
Rationale and Design of the FAIR-HF 2 trial: Ferric Carboxymaltose Assessment of Morbidity and Mortality in Patients with Iron Deficiency and Chronic Heart Failure.
Anker SD, Friede T, Butler J, Talha KM, Diek M, Nosko A, Placzek M, Hasenfuß G, Ponikowski P, Karakas M (2024). European Journal of Heart Failure.
